Post by
Nonyah on Jul 24, 2020 8:49am
Johnson & Johnson subsidiary Janssen approves Aleafia
Johnson & Johnson subsidiary Janssen approves Aleafia Health to admin Spravato. Spravato is a Ketamine based Nasal Spray which cost patients 3k- 5k per session. Currently, Aleafia Health has been approved for 3 locations to admin this drug from the gods. Totally, Aleafia Health has 25-40 locations Throughout Canada, some ready to admin and some clinics need retrofitting. Now that the clinics are fully paid for, the Sky is the limit
Comment by
OldSchooI on Jul 24, 2020 9:08am
You are correct...."sky is the limit." This is just the beginning. More news to follow ??? :) AHLooong!!!
Comment by
Nonyah on Jul 24, 2020 9:38am
im just thinking about the funding that will insue. JNJ will be able to help secure Aleafia Position in Canada has the Leading provider of Spravato Nasal Spray Clinics.
Comment by
KnowWhenToStfu on Jul 25, 2020 9:23pm
This post has been removed in accordance with Community Policy
Comment by
KnowWhenToHoldM on Jul 24, 2020 10:25am
This post has been removed in accordance with Community Policy
Comment by
Toweringmars on Jul 24, 2020 11:00am
Cool story bro... Mad at me for "pumping" but you also want the price to go up? Thats not two conflating view points at all.
Comment by
KnowWhenToStfu on Jul 24, 2020 11:10am
This post has been removed in accordance with Community Policy
Comment by
KnowWhenToStfu on Jul 24, 2020 10:49pm
This post has been removed in accordance with Community Policy
Comment by
OldSchooI on Jul 24, 2020 11:13am
It is interesting that a company with a market cap of $390b has taken interest in Aleafia. Must be doing something right! More to come?? :) AHLooong!!!